Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nihon Chouzai to Open More Stores Filling Prescriptions from Wide Range of Med Institutions
June 6, 2011
- Pfizer Japan Signs Comprehensive Agreement with NCC for Clinical Trials of Anticancer Drugs
June 6, 2011
- Kantar Health Highlights Crizotinib
June 6, 2011
- R&I Downgrades Takeda Following Announcement of Acquisition of Nycomed
June 6, 2011
- Nippon Zoki, Teikoku Seiyaku to Codevelop Adhesive Agent for PHN
June 6, 2011
- Daiichi Sankyo Aims for Sales of ¥40 Bil. in China
June 6, 2011
- HPV Vaccine Gardasil Recommended for Approval
June 6, 2011
- ¥45.5 Billion Worth of New-type Flu Vaccines Discarded: Health Minister Hosokawa
June 6, 2011
- PIII Clinical Trial of Lu AA21004 for MDD Starts in Japan: Takeda
May 30, 2011
- Otsuka Announces 1st Midterm Management Plan
May 30, 2011
- BI, Eli Lilly Obtain Approval for Linagliptin in US
May 30, 2011
- Takara Bio Aims for Sales of \22.7 Bil. in FY2013
May 30, 2011
- Terumo Starts Domestic Clinical Study of Acetaminophen
May 30, 2011
- Mediceo: Yakkasa Reduction Rate of Just 0.5 Points in FY2010
May 30, 2011
- Sales Up 5.6% for Ethical Drugs in March Following Disaster: Crecon Research & Consulting
May 30, 2011
- Wholesale Business Deteriorating due to War for Market Share: Mr Hamada of Toho HD
May 30, 2011
- Teva to Acquire Majority Stake in Taiyo
May 30, 2011
- Premium for New Drug Development an “Incentive”to Japan Business: Chairman Viehbacher of PhRMA
May 30, 2011
- Teva-Taiyo Strategic Tie-up to Have “No Major Impact”on Sawai: President Sawai
May 30, 2011
- Astellas Completes Acquisition of Perseid
May 30, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…